European Physician Adoption of Advanced Mobile Activities is Increasing

Manhattan ResearchAs mobile devices become more advanced, European physicians are turning to them for a number of uses in their professional practice, according to a recent study by Manhattan Research. About half of online European physicians check email on their mobile devices while nearly four in ten search on a mobile web browser. When it comes to mobile activities for medical content, physicians are currently more likely to conduct straightforward advanced tasks such as reading medical news or checking treatment guidelines, but as physicians' mobile proficiency continues to increase and as browsing capabilities improve, physicians will begin to perform more complex, interactive activities on these devices, such as social networking and patient monitoring.

"As in the U.S., mobile devices are streamlining the medical profession in Europe by allowing doctors to communicate and access clinical resources throughout the day," said Joe Farris, President of Manhattan Research. "While the largest current opportunity for connecting with European physicians is through brief, text-based content, there's future market potential for richer, more engaging mobile interactions."

Complimentary White Paper
Manhattan Research's European eHealth Landscape is a complimentary white paper discussing some of the latest trends in how physicians and patients across Europe use the Internet and technology for health purposes. To access the report, please visit http://www.manhattanresearch.com/research/white-papers/european-ehealth-landscape.aspx.

Manhattan Research eHealth Trends Podcast Series
Manhattan Research produces monthly podcasts on a variety of consumer and physician eHealth topics. In the latest episode, "EU vs. US physicians," Healthcare Analyst Miranda Manganaro discusses differences between European and US physicians when it comes to technology adoption and behavior. Free subscriptions are available immediately via iTunes at http://tinyurl.com/mRiTunes and you can listen to the entire series at http://www.manhattanresearch.com/podcast.

About Taking the Pulse® Europe
Taking the Pulse® Europe is Manhattan Research's market research and advisory service focused on how physicians across Western Europe use the Internet and technology for clinical purposes and for engaging with pharmaceutical companies. Taking the Pulse® Europe v9.0 was fielded online in Q4 2009 among 1,125 practicing physicians in Germany, Spain, France, Italy, and the United Kingdom.

Taking the Pulse® Europe provides in-depth market research on many other physician technology and digital marketing topics, including email communication, smartphone ownership/mobile activities, online journals, virtual conferences, social networking, online video, health and medical website visitation, search engines, patient education, pharma website visitation, videoconferencing with reps, and electronic detailing. In addition to a comprehensive view of the European physician market, clients can also gain insight into the online resource and communication trends for specific country and specialist segments. For more information, please visit http://www.manhattanresearch.com/ttpeu.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm. We conduct annual research studies covering eHealth trends among physicians and consumers in the U.S., Europe, and Asia.

For information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Novartis successfully completes acquisition of Xii…

Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to trea...

LEO Pharma completes the acquisition of Bayer’s pr…

LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO P...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

New study showing drug prolongs life for patients …

Women with ovarian cancer who have undergone four or more rounds of chemotherapy typically haven't had much hope that another treatment option will lengthen their lives i...

Pfizer completes acquisition of Therachon

Pfizer Inc. (NYSE: PFE) announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the ...